Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | DBH | P09172 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25139482 | 0.87 | HDAC1 (0.53) | CYP1A2CYP3A4MAOAMAOBPTGS2 | |
| SCHEMBL12337833 | 0.82 | CYP1A2 (0.51) | CYP1A2CYP3A4NAPRTMAOAMAOB | |
| SCHEMBL27480368 | 0.82 | CYP1A2 (0.51) | CYP1A2CYP3A4NAPRTMAOAMAOB | |
| SCHEMBL7302432 | 0.82 | CYP1A2 (0.51) | CYP1A2CYP3A4NAPRTMAOAMAOB | |
| SCHEMBL1887807 | 0.82 | CYP1A2 (0.51) | CYP1A2CYP3A4NAPRTMAOAMAOB | |
| SCHEMBL10121174 | 0.82 | KDM4E (0.62) | ALDH1A1LMNAKDM4EGAADBH | |
| SCHEMBL3844697 | 0.80 | NAPRT (0.52) | CYP1A2CYP3A4NAPRTMAOAMAOB | |
| Bromide SCHEMBL4188500 | 0.80 | CYP1A2 (0.50) | CYP1A2CYP3A4NAPRTMAOAMAOB | |
| Hydrochloric Acid SCHEMBL9425932 | 0.80 | CYP3A4 (0.50) | CYP1A2CYP3A4NAPRTMAOAMAOB | |
| Hydrochloric Acid SCHEMBL10500949 | 0.80 | CYP3A4 (0.50) | CYP1A2CYP3A4NAPRTMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3244987-A1 | SEPARATIONS WITH IONIC LIQUID SOLVENTS | Chevron Phillips Chemical Company LP (US) | 2017-11-22 | — | — | EP | claimed |
| WO-2025233901-A1 | ACTIVATORS OF PYRUVATE KINASE ISOFORM M2 AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-13 | — | — | WO | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023133507-A1 | ESTRADIOL PRODRUGS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20080014207-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2008-01-17 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070219140-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-09-20 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070167456-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | LOMMEN GUY R E | 2007-07-19 | — | — | US | disclosed |
| US-20070167456-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | LOMMEN GUY R E | 2007-07-19 | — | — | US | disclosed |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093429-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | CYP1A2 4786/4885CYP3A4 4804/4885NAPRT 1683/4885 |
| US-20080014207-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | CYP1A2 4786/4885CYP3A4 4804/4885NAPRT 1683/4885 |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | CYP1A2 1463/4885CYP3A4 1734/4885NAPRT 979/4885 |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | BAD, BIRC5, BAX | CYP1A2 4646/4885CYP3A4 4719/4885NAPRT 2372/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | CYP1A2 1682/4885CYP3A4 2422/4885NAPRT 3/4885 |
| US-20070219140-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC8 | CYP1A2 4724/4885CYP3A4 4753/4885NAPRT 1385/4885 |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | CYP1A2 437/4885CYP3A4 71/4885NAPRT 1572/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | CYP1A2 2469/4885CYP3A4 2815/4885NAPRT 694/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | CYP1A2 467/4885CYP3A4 47/4885NAPRT 1154/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CYP1A2 1069/4885CYP3A4 1880/4885NAPRT 3767/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | CYP1A2 4154/4885CYP3A4 4637/4885NAPRT 2446/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | CYP1A2 2970/4885CYP3A4 4070/4885NAPRT 3615/4885 |
| US-20070167456-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | CCR2, CCR1, CCR5 | CYP1A2 913/4885CYP3A4 875/4885NAPRT 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.